Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03215095
Title RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

thyroid gland follicular carcinoma

thyroid gland papillary carcinoma

thyroid gland Hurthle cell carcinoma

Therapies

Durvalumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.